Literature DB >> 16287071

Quantitative analysis of aromatase mRNA expression derived from various promoters (I.4, I.3, PII and I.7) and its association with expression of TNF-alpha, IL-6 and COX-2 mRNAs in human breast cancer.

Natsumi Irahara1, Yasuo Miyoshi, Tetsuya Taguchi, Yasuhiro Tamaki, Shinzaburo Noguchi.   

Abstract

The purpose of the present study was to study the aromatase mRNA expression as well as promoter usage (I.4, I.3, PII and I.7) in axillary adipose tissue (AA), mammary adipose tissue (MA), breast tumor tissue (BT) and adjacent normal breast tissue (NB), and to study the relationship between aromatase mRNA expression and tumor necrosis factor (TNF)-alpha, interleukin (IL)-6 and cyclooxygenase (COX)-2 mRNA expression. BT (n=108), NB (n=54), AA (n=41) and MA (n=34) from patients with breast cancer were subjected to real-time PCR assays for the mRNA levels of aromatase, TNF-alpha, IL-6 and COX-2. We also studied the usage of promoters I.4, I.3, PII and the recently reported endothelial promoter I.7. Total aromatase mRNA levels were significantly up-regulated in BT as compared with NB, AA and MA. Proportion of promoter l.4-specific transcripts against the total transcripts was significantly decreased and that of promoter l.3- and l.7-specific transcripts was significantly increased in BT than NB, AA and MA. However, the amount of transcripts from all the 4 promoters was significantly up-regulated in BT than NB, AA and MA. Estrogen receptor-alpha (ER-alpha) positive tumors showed a higher percentage of promoter I.7 usage than ER-alpha negative tumors with a marginal significance (p=0.05), and tumor with high microvessel counts tended (p=0.06) to show a higher percentage of promoter I.7 usage than those with low microvessel counts. There was a significant association between aromatase mRNA levels and TNF-alpha, IL-6 or COX-2 mRNA levels in BT, AA and MA but not in NB. These results suggest that enhanced transcription of promoters l.4, I.3, PII and I.7 explains the up-regulation of aromatase mRNA levels in BT. It has also been suggested that angiogenesis might stimulate the growth of ER-alpha positive tumors through the enhanced transcription of aromatase from promoter I.7 in endothelial cells in BT, and that TNF-alpha, IL-6 and COX-2 might be implicated in the up-regulation of aromatase mRNA in BT, AA and MA but not in NB. Copyright (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16287071     DOI: 10.1002/ijc.21562

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  42 in total

Review 1.  Aromatase, breast cancer and obesity: a complex interaction.

Authors:  Serdar E Bulun; Dong Chen; Irene Moy; David C Brooks; Hong Zhao
Journal:  Trends Endocrinol Metab       Date:  2011-12-12       Impact factor: 12.015

Review 2.  Minireview: Inflammation: an instigator of more aggressive estrogen receptor (ER) positive breast cancers.

Authors:  Sarah C Baumgarten; Jonna Frasor
Journal:  Mol Endocrinol       Date:  2012-02-02

Review 3.  Structural and functional characterization of aromatase, estrogen receptor, and their genes in endocrine-responsive and -resistant breast cancer cells.

Authors:  Hei Jason Chan; Karineh Petrossian; Shiuan Chen
Journal:  J Steroid Biochem Mol Biol       Date:  2015-08-13       Impact factor: 4.292

Review 4.  The role of cytokines in breast cancer development and progression.

Authors:  Marcela Esquivel-Velázquez; Pedro Ostoa-Saloma; Margarita Isabel Palacios-Arreola; Karen E Nava-Castro; Julieta Ivonne Castro; Jorge Morales-Montor
Journal:  J Interferon Cytokine Res       Date:  2014-07-28       Impact factor: 2.607

Review 5.  Molecular mechanisms of the preventable causes of cancer in the United States.

Authors:  Erica A Golemis; Paul Scheet; Tim N Beck; Eward M Scolnick; David J Hunter; Ernest Hawk; Nancy Hopkins
Journal:  Genes Dev       Date:  2018-06-26       Impact factor: 11.361

Review 6.  Signals from the Adipose Microenvironment and the Obesity-Cancer Link-A Systematic Review.

Authors:  Caroline Himbert; Mahmoud Delphan; Dominique Scherer; Laura W Bowers; Stephen Hursting; Cornelia M Ulrich
Journal:  Cancer Prev Res (Phila)       Date:  2017-09

7.  A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole.

Authors:  Zaida Garcia-Casado; Angel Guerrero-Zotano; Antonio Llombart-Cussac; Ana Calatrava; Antonio Fernandez-Serra; Amparo Ruiz-Simon; Joaquin Gavila; Miguel A Climent; Sergio Almenar; Jose Cervera-Deval; Josefina Campos; Carlos Vazquez Albaladejo; Antonio Llombart-Bosch; Vicente Guillem; Jose A Lopez-Guerrero
Journal:  BMC Cancer       Date:  2010-02-09       Impact factor: 4.430

Review 8.  Obesity and inflammation: new insights into breast cancer development and progression.

Authors:  Neil M Iyengar; Clifford A Hudis; Andrew J Dannenberg
Journal:  Am Soc Clin Oncol Educ Book       Date:  2013

9.  Rs1008805 polymorphism of CYP19A1 gene is associated with the efficacy of hormone therapy in stage I-II and operable stage III breast cancer.

Authors:  Xiying Shao; Lei Luo; Yong Guo; Xiaohong Xu; Dehou Deng; Jianguo Feng; Yuheng Ding; Hanzhou Mou; Ping Huang; Lei Shi; Yuan Huang; Weiwu Ye; Caijin Lou; Zhanhong Chen; Yabing Zheng; Xiaojia Wang
Journal:  Oncol Lett       Date:  2017-09-18       Impact factor: 2.967

Review 10.  Targeting obesity-related adipose tissue dysfunction to prevent cancer development and progression.

Authors:  Ayca Gucalp; Neil M Iyengar; Clifford A Hudis; Andrew J Dannenberg
Journal:  Semin Oncol       Date:  2015-09-08       Impact factor: 4.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.